Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 4, 2010

Circulating procalcitonin in aseptic carcinoma patients: a specificity study with 18F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark

  • Luca Giovanella , Sergio Suriano , Riccardo Ricci , Paolo Ravani and Luca Ceriani

Abstract

Background: The goal of the study was to evaluate the specificity of serum procalcitonin (PCT) in a large cohort of patients with solid carcinomas at different stages.

Methods: The study involved 447 patients having histologically confirmed carcinoma of the breast, head and neck, ovary, cervix or non-small cell lung carcinoma. Patients with a history of small cell lung cancer, neuroendocrine tumors, medullary thyroid carcinoma, sepsis, systemic inflammatory syndrome, renal failure and/or serum C-reactive protein above 5 ng/mL were excluded. Additionally, those with suspicious infectious or inflammatory diseases in 18F-fluorodeoxyglucose positron-emission tomography/computed tomography were also excluded. Serum PCT concentrations were measured using a Kryptor system (BRAHMS) and a clinical cut-off at 0.5 ng/mL was used to define positive results.

Results: Serum PCT concentrations did not change at different cancer stages (Kruskal-Wallis, p>0.05). No patient had a PCT concentration >0.5 ng/mL.

Conclusions: Our data show that solid carcinomas “per se” did not increase circulating PCT concentrations, regardless of the histotype and stage of the disease.

Clin Chem Lab Med 2010;48:1163–5.


Corresponding author: PD Dr. med. Luca Giovanella, Nuclear Medicine and Thyroid Center, Oncology Institute of Southern Switzerland, Via Ospedale 12, 6500 Bellinzona, Switzerland Phone: +91-811-8672, Fax: +91-811-8250,

Received: 2009-12-24
Accepted: 2010-2-4
Published Online: 2010-05-04
Published in Print: 2010-08-01

©2010 by Walter de Gruyter Berlin New York

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2010.214/pdf
Scroll to top button